Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The project award will support late-stage development for an mRNA-based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus. This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population. The agreement also includes additional options to prepare and accelerate aresponse to future public health threats.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s RSV Vaccine Nears EU Approval
- Moderna announces positive CHMP opinion for marketing authorization of mRESVIA
- Carisma Therapeutics nominates first candidate under collaboration with Moderna
- GSK, Pfizer under pressure after CDC narrows RSV shots age recommendation
- GSK, Pifzer RSV franchises ‘delivered a blow,’ says Citi